CD274 and neoplasm: Therefore, it is feasible to combine radiotherapy and immunotherapy based on the immune-stimulating properties of radiotherapy.PD-1/PD-L1 inhibitor has been approved for the treatment of oesophageal, head and neck, melanoma, kidney, bladder, lung cancers and other tumours.